On December 3, 2020 TG Therapeutics, Inc. (NASDAQ: TGTX), reported the schedule of data presentations at the upcoming 62nd American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting and exposition, to be held virtually December 5 – 8, 2020 (Press release, TG Therapeutics, DEC 3, 2020, View Source [SID1234572130]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ASH 2020 PRESENTATION DETAILS:

Oral Presentation Title: Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 UNITY-CLL Study
Publication Number: 543
Oral Session: 642. CLL: Therapy, excluding Transplantation
Session Date and Time: Monday, December 7, 2020; 7:00 AM – 8:30 AM (Pacific Time)
Presentation Time: 7:15 AM (Pacific Time)
Presenter: John G. Gribben, MD, D.Sc., Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom;
Poster Presentation Title: Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global UNITY-NHL Trial
Publication Number: 2934
Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
Date and Time: Monday, December 7, 2020; 7:00 AM – 3:30 PM (Pacific Time)
Presenter: Pier Luigi Zinzani, MD, PhD, Institute of Hematology, "L. e A. Seràgnoli", University of Bologna, Italy

Poster Presentation Title: A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Publication Number: 3137
Session: 642. CLL: Therapy, excluding Transplantation: Poster III
Date and Time: Monday, December 7, 2020; 7:00 AM – 3:30 PM (Pacific Time)
Presenter: Paul M. Barr, MD, Wilmot Cancer Institute, University of Rochester Medical Center, NY

Poster Presentation Title: Clinical Activity of TG-1701, As Monotherapy and in Combination with Ublituximab and Umbralisib (U2), in Patients with B-Cell Malignancies
Publication Number: 1130
Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I
Date and Time: Saturday, December 5, 2020; 7:00 AM – 3:30 PM (Pacific Time)
Presenter: Chan Y. Cheah MBBS, DMSc, Linear Clinical Research, and Department of Haematology, Sir Charles Gairdner Hospital, Nedlands Western Australia, Medical School, University of Western Australia, Crawley, Western Australia
Following each presentation during ASH (Free ASH Whitepaper) 2020, the data presented will be available on TG’s corporate website at View Source TG abstracts are publicly available via the ASH (Free ASH Whitepaper) meeting website at www.hematology.org or on the company’s corporate website.